InnoCan Financial Statements From 2010 to 2026
| INNPF Stock | USD 5.76 0.16 2.70% |
Check InnoCan Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among InnoCan Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . InnoCan financial statements analysis is a perfect complement when working with InnoCan Pharma Valuation or Volatility modules.
InnoCan |
InnoCan Pharma OTC Stock Profit Margin Analysis
InnoCan Pharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current InnoCan Pharma Profit Margin | (2.17) % |
Most of InnoCan Pharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InnoCan Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, InnoCan Pharma has a Profit Margin of -2.1729%. This is 80.62% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all United States stocks is 71.09% higher than that of the company.
InnoCan Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining InnoCan Pharma's current stock value. Our valuation model uses many indicators to compare InnoCan Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across InnoCan Pharma competition to find correlations between indicators driving InnoCan Pharma's intrinsic value. More Info.InnoCan Pharma is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the InnoCan Pharma's earnings, one of the primary drivers of an investment's value.About InnoCan Pharma Financial Statements
InnoCan Pharma stakeholders use historical fundamental indicators, such as InnoCan Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although InnoCan Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in InnoCan Pharma's assets and liabilities are reflected in the revenues and expenses on InnoCan Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in InnoCan Pharma. Please read more on our technical analysis and fundamental analysis pages.
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol with other pharmaceutical ingredients in the United States, Poland, France, and internationally. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada. Innocan Pharma is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in InnoCan OTC Stock
InnoCan Pharma financial ratios help investors to determine whether InnoCan OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in InnoCan with respect to the benefits of owning InnoCan Pharma security.